CBIO analyst estimates
Crescent Biopharma (CBIO) analyst ratings, the average price target and its range, and every firm's latest call.
- 2 firms rate CBIO: 2 buy, 0 hold, 0 sell.
- The average price target is $36.00 from None analysts, from $36.00 to $36.00.
CBIO analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 19, 2026 | UBS | H.C. Wainwright Reiterates Buy Rating on Crescent Biopharma Inc (CBIO) | $36.00 |
| Oct 6, 2026 | H.C. Wainwright | Crescent Biopharma upgraded to Buy from Neutral at H.C. Wainwright | $36.00 |
| Feb 26, 2026 | Stifel Nicolaus | Crescent Biopharma Inc (CBIO) PT Lowered to $29 at Stifel | $29.00 |
| Jan 28, 2026 | Piper Sandler | Crescent Biopharma initiated with an Overweight at Piper Sandler | $35.00 |
| Jan 21, 2026 | Guggenheim | Crescent Biopharma initiated with a Buy at Guggenheim | $35.00 |
| Dec 4, 2025 | Stifel Nicolaus | Crescent Biopharma price target raised to $32 from $28 at Stifel | $32.00 |
| Aug 25, 2025 | Jefferies | Crescent Biopharma initiated with a Buy at Jefferies | $26.00 |